Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.
Shares of Mallinckrodt Plc plunged more than 30 percent to an all-time low on Tuesday after the drugmaker reported disappointing quarterly revenue and warned of slower sales of Acthar, its biggest source of revenue.
U.S. drug distributor Cardinal Health Inc's quarterly revenue fell short of analysts' forecasts, as prices for generic drugs remained stubbornly low, sending the company's shares down to a four-year low on Monday.
Shares of WellCare Health Plans Inc hit a record high on Tuesday after the health insurer handily beat analysts' estimates for third-quarter profit, keeping costs in check at its Medicaid business and adding thousands of new members to its Medicare plans.
Endo International Plc on Monday gave a glimpse of a quarter that could help ease investor concerns when it announced preliminary earnings well above market estimates, sending the generic-drug maker's shares up as much as 18 percent.
Laboratory Corp of America Holdings' profit topped analysts' estimates and the company raised its full-year revenue growth forecast on Wednesday, expecting growth from its diagnostics business.
Biogen Inc's shares dived 8 percent on Tuesday after U.S. sales of Spinraza, a potential blockbuster drug it is banking on to offset slowing sales of multiple sclerosis drugs, fell short of Wall Street estimates in the latest quarter.
Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.
Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.
Amneal Pharmaceuticals LLC is buying fellow generics drug maker Impax Laboratories Inc in an all-stock deal as a bulwark against a tough drug pricing environment.